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Abstract: Therapeutic enzymes are administered for the treatment of a wide variety of diseases.
They exert their effects through binding with a high affinity and specificity to disease-causing
substrates to catalyze their conversion to a non-noxious product, to induce an advantageous
physiological change. However, the metabolic and clinical efficacies of parenterally or intramuscularly
administered therapeutic enzymes are very often limited by short circulatory half-lives and
hypersensitive and immunogenic reactions. Over the past five decades, the erythrocyte carrier
has been extensively studied as a strategy for overcoming these limitations and increasing therapeutic
efficacy. This review examines the rationale for the different therapeutic strategies that have been
applied to erythrocyte-mediated enzyme therapy. These strategies include their application as
circulating bioreactors, targeting the monocyte–macrophage system, the coupling of enzymes to
the surface of the erythrocyte and the engineering of CD34+ hematopoietic precursor cells for the
expression of therapeutic enzymes. An overview of the diverse biomedical applications for which
they have been investigated is also provided, including the detoxification of exogenous chemicals,
thrombolytic therapy, enzyme replacement therapy for metabolic diseases and antitumor therapy.
Keywords: carrier erythrocytes; erythrocyte carriers; enzyme replacement therapies; therapeutic
enzymes; thrombolytic therapy; drug delivery; erythrocyte bioreactor
1. Introduction
Therapeutic enzymes are biocatalyst drugs that bind to target substrates with a high affinity and
specificity, catalyzing their conversion into their relevant products. The past five decades have seen
the development of therapeutic enzymes for treating a wide range of medical conditions, including
inherited enzyme deficiency disorders, acute poisoning, digestive disorders, cancer and cardiovascular
diseases. Chemical modifications of the native enzyme (e.g., conjugation with polyethylene glycol) are
often employed in the manufacturing process to increase protein stability, decrease immunogenicity,
reduce renal ultrafiltration and in some cases, to enable targeting of the enzyme to the appropriate
cellular compartment [1]. However, despite these strategies, the metabolic and clinical efficacy of
parenterally or intramuscularly administered therapeutic enzymes is still limited. This is principally
due to short circulatory half-lives, hypersensitivity reactions and immunogenicity. Immune responses
are influenced by several factors including the biophysical characteristics of the protein, the route of
delivery, the degree of exposure and the use of immunosuppressive agents during administration.
Host factors may also play a part, for example patients with congenital enzyme deficiencies may fail to
recognize a therapeutic protein as “self” and may be more likely to mount an immune response during
the administration of therapeutic replacement enzyme [2]. The consequences of an immune reaction to
a therapeutic enzyme range from a transient appearance of antibodies, without any clinical sequel,
to severe life-threatening conditions.
The erythrocyte carrier has been extensively studied as a strategy for overcoming these limitations
and increasing therapeutic efficacy. For a majority of the therapeutic applications investigated,
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the ability of the cell to reseal after creating pores in the membrane has been exploited for the purpose
of introducing therapeutic agents [3–5]. The resealed erythrocyte is biocompatible and, in the human,
has a normal in vivo circulating half-life of 19–29 days, and thus raises the potential to extend the
half-life of encapsulated enzymes through the avoidance of plasma clearance due to the action of
proteases, anti-enzyme antibodies and renal clearance, and through minimizing immune reactions.
The aim of this article is to provide a review of the available literature relating to in vitro,
preclinical and clinical studies of the erythrocyte as a vehicle for therapeutic enzymes.
2. Therapeutic Strategies
Four main therapeutic strategies have been applied to the erythrocyte carrier in terms of a vehicle
for therapeutic enzymes. In the first, enzyme-loaded erythrocytes can be employed as circulating
bioreactors whereby blood-based molecules diffuse into the erythrocyte and are degraded. This strategy
is relevant to the treatment of congenital enzyme-deficiencies where a pathologically elevated plasma
metabolite is able to permeate erythrocyte membrane and undergo metabolism to the normal product [6].
Also relevant to this therapeutic strategy is the depletion of plasma metabolites for the treatment of
auxotrophic tumors and detoxification after exposure to toxic chemicals, Figure 1.
The second strategy involves the targeting of encapsulated enzymes to the monocyte–macrophage
system of the spleen, liver and bone marrow, through exploiting the natural sites of
erythrophagocytosis [7]. The loss of phospholipid asymmetry and the exposure of phosphatidylserine
on the surface of the plasma membrane of senescence erythrocytes induces erythrocyte sequestration
by macrophages. As erythrocyte degradation occurs in the lysosomal compartment of macrophages,
it is proposed that erythrocyte encapsulated enzymes can potentially target macromolecules that
accumulate in the lysosomal compartment as a result of congenital enzyme-deficiencies, Figure 2.
The third strategy involves the coupling of therapeutic enzymes to the erythrocyte surface with
the aim of improving the therapeutic profile, Figure 3.
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Figure 4. Strategy for therapeutic enzymes produced through the transfection of CD34+ cells with
lentiviral vectors containing constructs encoding for the enzyme of interest. Cells are expanded
and differentiated until the nucleus is ejected, resulting in the mature reticulocyte expressing the
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3. Therapeutic Applications
Over the past five decades, the erythrocyte carrier has been extensively investigated as a potential
modality for targeting a wide range of therapeutic applications. In relation to carriers of enzymes,
these applications can broadly be divided into four key areas of research interest: exogeneous chemical
detoxification, thrombolytic therapy, treatments for metabolic diseases and antitumor therapies.
Although a majority of these studies have not translated beyond the pre-clinical stage, a few are
currently undergoing clinical development. The following provides a discussion of the applications
investigated under these four research areas.
3.1. Detoxification of Exogenous Chemicals
The utility of the erythrocyte as a carrier of specific enzymatic antidotes against chemical intoxicants
has been investigated by a number of groups. Investigations into this therapeutic application have
focused on encapsulating the relevant enzyme within the erythrocyte. Way et al. first established the
potential of the erythrocyte carrier as antidote candidate for cyanide intoxication [8,9]. Cyanide is
a rapidly lethal poison and exerts its toxic effect by blocking the mitochondrial respiration chain
and the formation of intracellular adenosine triphosphate through binding to cytochro e-c oxidase,
the terminal enzyme complex of the respiratory chain in complex IV. Sodium thiosulfate is one of the
antidotes used to combat intoxication and works by acting as a sulfur donor for the mitochondrial
enzyme, thiosulfate sulfotransferase (rhodanase, EC 2.8.1.1) [10]. Sodium thiosulfate does not readily
permeate cell membranes and therefore is not able to distribute to sites of thiosulfate sulfotransferase or
cyanide localization; this provided the rationale for investigating the erythrocyte carrier as an alternative
approach to cyanide antagonism. In vivo studies in mice demonstrated that erythrocytes containing
sodium thiosulfate and rhodanase could rapidly metabolize cyanide to the less toxic thiocyanate and
antagonize the effects of a lethal dose of potassium cyanide [11–13]. Moreover, by replacing sodium
thiosulfate with butanethiosulfonate, a more reactive sulfur donor substrate, an enhanced protective
effect against cyanide was found [14].
The application of the erythrocyte carrier as an antagonist of the lethal effects of parathion, a once
widely used agricultural organophosphorous insecticide was also investigated as an alternative antidote
approach to paraoxon intoxication. The toxicity of parathion is attributed to its in vivo metabolism
to paraoxon which inhibits acetylcholinesterase, leading to an accumulation of acetylcholine and
ultimately altering cholinergic synaptic transmission at neuroeffector junctions, at skeletal myoneural
junctions and autono ic ganglia in the central nervous system [15]. Two antidotes for parathion
poisoning are atropine, a competitive antagonist of acetylcholine at the muscarinic receptor and
pralidoxime, which regenerates acetylcholinesterase [16]. However, neither of these antidotes are able
to degrade parathion. In vivo studies in mice investigated the efficacy of erythrocyte encapsulated
phosphotriesterase (EC 3.1.8.1) in antagonizing the lethal effects of paraoxon through its hydrolysis
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to the less toxic 4-nitrophenol and diethylphosphate [17]. The results indicated that although the
phosphotriesterase-loaded erythrocytes were more effective than the classic antidotal combination
of atropine and pralidoxime, a combination of the loaded erythrocytes with the classic antidot,
provided a 1000-fold protection against paraoxon. The same group also investigated the application of
erythrocyte encapsulated recombinant paraoxonase as an approach to directly hydrolyze paraoxon;
treated mice showed no signs of intoxication at paraoxon dose levels that were lethal when using
the classical antidotal combination of atropine and pralidoxime. Moreover, erythrocyte encapsulated
paraoxonase, in combination with the classic antidotal combination, provided the highest antidotal
efficacy ever reported against any chemical toxicant [18].
Another category of detoxifying enzymes that have been investigated are those associated with
the metabolism of ethanol and methanol. Ethanol detoxification requires two enzymic reactions:
the oxidation of ethanol to acetaldehyde by alcohol dehydrogenase (EC. 1.1.1.1), followed by
the oxidation acetaldehyde to acetate by aldehyde dehydrogenase (EC 1.2.1.5). Chronic alcohol
consumption decreases acetaldehyde oxidation, either due to decreased aldehyde dehydrogenase
activity or impaired mitochondrial function. The application of the erythrocyte carrier as an alcohol
detoxifier was first proposed by Magnani et al. They demonstrated that mice administered acetaldehyde
dehydrogenase-loaded erythrocytes intraperitoneally had 35% less blood acetaldehyde compared
to controls, one hour after receiving an acute dose of ethanol [19]. Lizano et al. investigated the
co-encapsulation of alcohol dehydrogenase and aldehyde dehydrogenase in human erythrocytes,
demonstrating their superior ability to metabolize ethanol in vitro, compared to erythrocytes loaded
with alcohol dehydrogenase alone [20]. In vivo studies in mice receiving acute doses of ethanol and
treated with co-encapsulated enzymes showed blood ethanol to be eliminated at rates of 1.7 mmol/L to
4 mmol/L loaded erythrocytes/hour [21,22]. However, these rates of plasma ethanol clearance were
lower by an order of magnitude than those expected from the activities of encapsulated enzymes.
By employing a mathematical modeling approach and then conducting a subsequent in vitro study,
Alexandrovich et al. were able to theorize and then demonstrate the rate limiting step of external
ethanol oxidation. They found this was due to the rate of nicotinamide–adenine dinucleotide (NAD+)
generation in erythrocyte glycolysis, rather than the activities of the loaded enzymes. By supplementing
the erythrocytes with NAD+ and pyruvate they were able to demonstrate an elimination of 17 mmol
ethanol/L loaded erythrocytes/hour [23].
In mammalian species, methanol is metabolized to formaldehyde via alcohol dehydrogenase,
followed by the conversion of formaldehyde into formic acid via aldehyde dehydrogenase. Formic acid
metabolism is mediated through a tetrahydrofolate-dependent pathway by folate-dependent enzymes.
Humans have 60% less liver folate concentrations compared to mice and rats, and for this reason
humans are more sensitive to methanol poisoning [24]. Specifically, formic acid inhibits mitochondrial
cytochrome c oxidase, leading to cellular hypoxia and metabolic acidosis. Magnani et al. investigated
the application of erythrocyte-encapsulated methylotrophic yeast alcohol oxidase (EC 1.1.3.13) as
an approach to the detoxification of methanol. In vivo studies showed that two hours following an acute
dose of methanol (0.7 g/kg), mice that had received enzyme-loaded erythrocytes had 50% less blood
methanol compared to controls, with antagonism persisting for at least one week [25]. On the basis that
formate dehydrogenase (EC 1.2.1.2) converts formate into CO2 in the presence of NAD, Muthuvel et al.
administered formate dehydrogenase-loaded erythrocytes to methanol-intoxicated folate-deficient rats,
which were pre-treated with carbicarb to correct the metabolic acidosis, and demonstrated a marked
elimination of formate [26].
A detoxifying enzyme that has been investigated in relation to lead poisoning is δ-aminolevulinic
acid dehydratase (E.C. 4.2.1.24). Lead is a potent inhibitor of δ-aminolevulinic acid dehydratase
through its displacement of zinc from the enzyme’s active site. The resulting inactivation leads to
an accumulation of its substrate, aminolevulinic acid, and this has been shown to have a neuropathogenic
effect [27]. The in vitro and in vivo mouse studies of Bustos et al. showed that it was possible to correct
the defective δ-aminolevulinic acid dehydratase activity in erythrocytes by encapsulating exogenous
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human enzyme, thus providing a rationale for this approach for treating lead intoxication [28,29].
In the first clinical application, 100 mL autologous erythrocytes loaded with 25,600 units of human
δ-aminolevulinic acid dehydratase were administered to a single patient with a history of chronic lead
intoxication, producing a reduction in blood lead concentration and decrease in urinary porphyrin
excretion, which was sustained for a period of four years [30].
Biochemical decompression has been proposed as a method for reducing the amount of time
required for deep-sea divers to return to the surface. Divers breathing H2/O2 mixtures would be
administered hydrogenase (EC 1.12.1.4), thus accelerating decompression through the removal of
excess hydrogen from the tissues. The application of erythrocyte encapsulated hydrogenase as
an approach to converting dissolved hydrogen gas into non-gaseous forms was investigated by
Axley et al. Hydrogenase activities of 7-µmol H2/minute/mL packed human erythrocytes were
successfully encapsulated, however the cells were not able to consume hydrogen due to the enzyme’s
dependence on NAD for activity. The co-encapsulation of FAD with hydrogenase was shown to
overcome this [31].
3.2. Thrombolytic Therapy
The application of erythrocytes as a strategy for thrombolytic therapy has been explored by
several groups. Thrombolytics (or fibrinolytics), also known as plasminogen activators, facilitate
the removal of pre-existing thrombotic clots through degrading the fibrin meshwork into plasmin.
However, their application is limited by their rapid clearance and inactivation by plasminogen activator
inhibitor-1, the risk of bleeding caused by dissolution of hemostatic clots and filtration into extravascular
tissues, such as the central nervous system, causing toxicity [32]. The rationale for the erythrocyte
encapsulation of fibrinolytics was based on addressing these issues with the study of Delahousse et al.
who successfully demonstrated the encapsulation of the fibrinolytic enzymes urokinase (EC 3.4.21.31),
streptokinase (EC 3.4.99.0) and recombinant tissue plasminogen activator (tPA; EC 3.4.21.68) in human
erythrocytes. However, in vitro stability studies using human erythrocytes and in vivo studies in
the mouse were not able to support the objective of a sustained half-life and demonstrated a rapid
destruction of the encapsulated enzymes [33]. Flynn and coworkers reported that Aspergillus oryzae
brinase (EC. 3.4.99) encapsulated into rabbit erythrocytes was able to lyse clotted blood in vitro [34].
The coupling of fibrinolytics to the surface of the erythrocyte carrier was proposed as a preferable
alternative to encapsulation [35]. Murciano et al. investigated the conjugation of tPA to erythrocytes
as a strategy for thromboprophylaxis, by employing mouse and rat models of venous and arterial
thrombosis. Following intravenous injection, the fibrinolytic activity of tPA conjugated to erythrocytes
was shown to persist in the circulation at least tenfold longer than that of free tPA. Free tPA was able to
lyse pulmonary clots that had lodged before administration, but not those that lodged after injection.
Erythrocyte conjugated-tPA, however was more selective in lysing nascent over preexisting pulmonary
emboli and arterial clots, an effect that is most likely a result of restricting the diffusion of tPA into
fibrin [36]. The utility of this approach in preventing cerebrovascular thrombosis was also examined
using mouse and rat models of cerebrovascular thromboembolism and ischemia, with the results
indicating that erythrocyte-conjugated tPA was an effective thromboprophylaxis, whereas free tPA
was ineffective up to a 10-fold higher dose [37].
Worthy of mention is the more recent studies investigating the erythrocyte carrier as a theranostic
nanoplatform system. This system consists of vesicles derived from erythrocytes that encapsulate
the NIR fluorophore, indocyanine green and of relevance to this review, the conjugation of tPA to
the vesicle surface. These constructs are referred to as NIR erythrocyte-derived transducers (NETS).
In vitro studies employing a clot model demonstrated the dual functionality of NETS in NIR imaging
and clot lysis [38].
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3.3. Enzyme Replacement for Metabolic Diseases
The application of the erythrocyte as a carrier of enzymes for the treatment of inherited metabolic
diseases and other metabolic disturbances has generated a large amount of interest from those working
in a field where there are enormous unmet needs. The following provides a discussion of the metabolic
disorders to which the erythrocyte carrier has been applied. With the exception of phenylketonuria,
these therapeutic applications have focused on the use of encapsulated enzyme.
3.3.1. Lysosomal Storage Disorders
Ihler et al. first proposed the erythrocyte carrier as a strategy for targeting enzyme replacement for
the treatment of disorders of sphingolipid catabolism, and successfully demonstrated the erythrocyte
encapsulation of β-glucosidase (EC.3.2.1.45) and β-galactosidase (EC 3.2.1.23) [3]. Sphingolipidoses are
a subgroup of lysosomal storage disorders characterized by an abnormal accumulation of phospholipids
that have a sphingosine group. The rationale for the therapeutic strategy is based on the erythrocyte
being naturally sequestered by cells of the monocyte–macrophage system and subsequent lysosomal
degradation at the subcellular site where the enzyme defect manifests, thereby facilitating the delivery
of the encapsulated enzyme to the site of phospholipid accumulation. Deloach and coworkers
demonstrated that human erythrocytes-loaded with E. coli β-galactosidase could be phagocytosed by
bone marrow macrophages that had been matured in vitro. Electron microscopy revealed that intact
or partly degraded erythrocytes were localized in intracellular vacuoles, which were presumed to be
phagolysosomes. The activity of the untaken β-galactosidase disappeared with a half-life of 15–30 h,
which was consistent with the enzyme being degraded within the lysosomes [39]. Studies comparing the
fate of erythrocyte-encapsulated bovine β-glucuronidase (EC 3.2.1.31) and free enzyme administered
intravenously to β-glucuronidase-deficient mice demonstrated that erythrocyte encapsulated enzyme
was retained four times longer in the circulation, five-fold longer in hepatic tissues and was more
efficiently delivered to a number of other tissues [40]. In 1977, Beulter et al. reported the first
clinical application of the erythrocyte carrier for the treatment of Gaucher disease (Online Mendelian
inheritance in Man (OMIM) # 230800, 230900, 231000). Gaucher disease is caused by mutations in the
GBA gene which encodes for the enzymeβ-glucocerebrosidase (also referred to asβ-glucosidase), which
catalyzes the hydrolysis of glucosylceramide into ceramide and glucose. A deficiency in the enzyme
leads to an accumulation of glucosylceramide in the lysosomes of macrophages in the liver, spleen and
bone marrow. The disease is classified into three clinical forms on the basis of neurological involvement:
type I (non-neuronopathic), type II (acute neuronopathic) and type III (subacute neuronopathic) with
all three having symptoms of hepatosplenomegaly, anemia and orthopedic complications [41]. In the
first clinical application, partially purified glucocerebrosidase isolated from the human placenta was
encapsulated into erythrocytes and administered to a single patient with advanced type I Gaucher
disease. Although there were no conclusive findings that enzyme infusion had been beneficial, this
study was able to demonstrate the safety of repeated administrations of enzyme encapsulation in
erythrocytes [42]. Studies investigating the in vitro uptake of glucocerebrosidase by Gaucher patient
monocytes demonstrated that enzyme loaded erythrocytes coated with human IgG and agglutinated
with anti-human serum were more avidly phagocytosed compared to uncoated loaded erythrocytes.
In addition, the uptake of enzyme via IgG-coated erythrocytes, was sufficient to normalize cellular
glucocerebrosidase activities for at least 18 h [43]. Bax et al. investigated the encapsulation of
mannose-terminated glucocerebrosidase (Alglucerase), a licensed pharmaceutical enzyme preparation
available for the treatment of Gaucher’s disease. This enzyme preparation has a plasma half-life of
3.6–10.4 min and thus, regular infusions are required to maintain therapeutic levels. Alglucerase
encapsulation was found to be maximized by employing the more concentrated pharmaceutical
preparation and doubling the hypo-osmotic dialysis time to 180 min [44,45]. Despite the erythrocyte
carrier offering a potential solution to the rapid plasma clearance and the prospect of reducing therapy
costs and the number of therapeutic interventions, this approach has not been advanced in the clinical
setting. The availability of a number of approved and effective enzyme replacement therapies for
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Gaucher disease that can be administered in the patient’s home no doubt would have contributed to
the lack of incentive in developing the erythrocyte carrier further for this disease.
3.3.2. Hyperammonemia
A number of groups have investigated the use of the erythrocyte carrier as an alternative approach
to treating metabolic disturbances characterized by an excess of ammonia in the blood. Ammonia is
produced by intestinal bacterial flora or as a metabolic byproduct of amino acid catabolism acid and other
compounds which contain nitrogen. Normally, ammonia is efficiently handled by the conversion to urea
via the urea cycle in the liver or by the reaction catalyzed by glutamine synthetase (EC 6.3.1.2). Congenital
deficiencies of enzymes in the urea cycle or diseases that lead to acute or chronic liver failure can result
in hyperammonemia, leading to nervous system disturbances, hepatic encephalopathy, coma and death.
The metabolic capability of the erythrocyte carrier in reducing blood ammonia concentrations has been
investigated by the encapsulation of two enzymes. In the first approach, l-glutamate dehydrogenase
(EC. 1.4.1.3) which catalyzes the formation of l-glutamic acid from α-ketoglutarate and ammonium
in the presence of NADPH was investigated. The second approach utilized glutamine synthetase
(EC. 6.3.1.2) which catalyzes the formation of l-glutamine from l-glutamic acid and ammonium in the
presence of ATP. Sanz et al. explored the former approach by examining the capability of encapsulated
glutamate dehydrogenase in removing extracellular ammonia in vitro by incubating human loaded
erythrocytes in buffer containing ammonium chloride, α-ketoglutarate and NADPH as substrates.
After 24 h of incubation, the ammonia concentration was 15 µmol/L, this representing 15% of the
zero time concentration and therefore providing support for this approach [46]. Subsequent in vivo
studies were performed in mice where hyperammonemia was induced through the intraperitoneal
injection of 33 U of urease/Kg of body weight. One hour after urease administration the blood
concentration of ammonia was 1333 µmol/L, and this declined to 135 µmol/L by 25 h. By administering
erythrocyte-encapsulated glutamate dehydrogenase to these mice, the blood concentration of ammonia
could be reduced by 50%, two hours after urease injection. The ammonia concentration remained
unchanged in control mice that received native washed erythrocytes [47]. Using the second approach,
Venediktova et al. examined the capability of erythrocytes loaded with glutamine synthetase to
eliminate ammonium from the blood of hyperammonemic mice. Blood ammonium concentrations
were shown to decrease by approximately 2-fold, 30 min after injection of the loaded cells and 4-fold
after 120 min, compared to ammonium concentration in control mice [48,49]. However, after this
time, the blood ammonium concentration decreased approximately at the same rate in both the
experimental and the control animals. To provide insight into this limitation, Protasov and coworkers
developed mathematical models of the erythrocyte carriers by focusing on the glycolytic pathway
reactions and enzymes utilizing ammonium. They concluded that the efficiency and duration of
the erythrocyte carrier function was limited by the low membrane permeability for α-ketoglutarate
and glutamate. To compensate the effect of this, the authors proposed the co-encapsulation of
glutamate dehydrogenase and alanine aminotransferase (EC 2.6.1.2). This approach created a metabolic
pathway where glutamic acid produced by the glutamate dehydrogenase reaction was converted
into α-ketoglutarate by alanine aminotransferase, with α-ketoglutarate then entering the glutamate
dehydrogenase reaction. Therefore, α-ketoglutarate and L-glutamic acid are produced and consumed
in a cyclical process and hence the system will independent of their transport. The conclusions of the
theoretical study were verified experimentally, demonstrating the removal of ammonium in vitro at the
rate of 1.5 mmol/h/ L human loaded erythrocytes and in a in vivo model of hyperammonemia in mice
at the rate of 2.0 mmol/h/L loaded erythrocytes [50].
An example of a urea cycle disorder that causes hyperammonemia is arginase-1 deficiency
(OMIM # 207800). This autosomal recessive disorder is caused by a mutation in the ARG1 gene.
Arginase (EC 3.5.3.1) normally controls the final step in the urea cycle through the hydrolysis of
arginine to urea and ornithine. Although a deficiency leads to an accumulation of arginine and
ammonia in the blood and cerebrospinal fluid, it is the accumulation of arginine which predominantly
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contributes to the pathological abnormality, with affected individuals experiencing development delay,
growth retardation and epileptic seizures [51]. Current treatments focus on reducing plasma ammonia
and arginine concentrations and reducing dietary nitrogen. Adriaenssens et al. explored the capacity
of arginase-loaded erythrocytes from patients with arginase deficiency to metabolize extracellular
arginine in vitro. They demonstrated that when the enzyme-loaded erythrocytes were incubated
in plasma containing 45 to 375 µmol/L arginine, the extracellular concentration of arginine was reduced
by 34% to 53% after one hour [52].
The utility of the erythrocyte as a carrier of urease (EC 3.5.1.5) for reducing blood concentrations
of urea in patients with chronic renal failure has been a long-term interest of Baysal et al. [53].
The rational for this approach is based on urease catabolizing urea into ammonia and bicarbonate,
followed by the catalytic conversion of ammonia and erythrocyte pyruvate into alanine by alanine
dehydrogenase (EC 1.4.1.1). The ultimate aim is to negate the requirement for hemodialysis and
continuous ambulatory peritoneal dialysis. Urease and alanine dehydrogenase and their pegylated
counterparts PEG–urease/PEG–alanine dehydrogenase were successfully encapsulated in human
erythrocytes [54,55]. In vivo studies in sheep employing erythrocytes containing PEG–urease and
PEG–alanine dehydrogenase at an activity unit ratio of 3:9 demonstrated a urea reduction of
51.6 mg/L/24 h. Compared to unencapsulated PEG–urease/PEG–alanine dehydrogenase, which was
able to reduce blood urea concentration by 21.7–61.6 mg/L for two days, the same dose encapsulated
in erythrocytes sustained these reductions for six days, thus demonstrating the utility of this system
in sustaining enzyme activity [56].
3.3.3. Hyperglycemia
The exploitation of enzyme-loaded erythrocytes in the regulation of diabetes associated
hyperglycemia was proposed by Magnani et al. who successfully encapsulated hexokinase (EC 2.7.1.1),
the first enzyme in the glycolytic pathway, responsible for catalyzing the phosphorylation of glucose
by ATP to glucose-6-phosphate. In vitro studies demonstrated that hexokinase-loaded erythrocytes
were able to metabolize twice the amount of extracellular glucose compared to unloaded cells,
however, this rate of metabolism was deemed insufficient for maintaining blood glucose within
the physiological concentrations [57]. De Flora and co-workers investigated the encapsulation of
glucose oxidase (EC 1.1.3.4) isolated from Aspergillus niger, another glucose catabolizing enzyme,
which converts glucose to hydrogen peroxide and D-glucono-δ-lactone. In vitro studies revealed that
glucose oxidase-loaded human and mouse erythrocytes were able to consume glucose 3–4 times faster
than the native, unloaded erythrocyte. However, there was a reported 10% increase in methemoglobin
formation and a several-fold increase in the activity of the pentose phosphate pathway, indicating
a glutathione peroxidase-mediated draining of reduced glutathione for removal of hydrogen peroxide
that was produced [58,59]. In vivo studies in the mouse demonstrated a drastically decreased half-life
of loaded cells of one to one and a half hours, compared to 10 days for unloaded erythrocyte carriers,
with a selective splenic uptake [59]. On the basis that the encapsulation of hexokinase not only
increases the glycolytic rate, but also the production of reducing equivalents (NADPH) in response
to an oxidative stress, Rossi et al. proposed the co-encapsulation of hexokinase and glucose oxidase
in human and mouse erythrocytes. Using this strategy, the authors were able maintain methemoglobin
concentrations within an acceptable range and demonstrate a large increase in glucose consumption [60].
In vivo studies in the diabetic mouse model, C57BL/Ks-db/db/01a, revealed that a single intraperitoneal
administration of hexokinase/glucose oxidase-loaded erythrocytes could sustain a near normal blood
glucose concentration for seven days, while repeated administrations at 10-day intervals were effective
in regulating blood glucose at physiological levels for more than 30 days [60].
3.3.4. Hyperlactatemia
The erythrocyte encapsulation of lactate 2-monooxygenase (EC 1.13.12.4) and L-lactate oxidase
(EC 1.1.3.2), two lactate-catabolizing enzymes, as strategies for the treatment for hyperlactatemia
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was explored by Garin et al. [61]. Lactate 2-mono-oxygenase metabolizes lactate in the presence
of oxygen to acetate and carbon dioxide, whereas lactate oxidase metabolizes lactate to pyruvate
and hydrogen peroxide. In vitro studies in mouse and human erythrocytes demonstrated that
encapsulated lactate 2-monooxygenase had a low affinity for lactate, operating at a low rate in the
presence of lactate concentrations found in hyperlactatemia (5–20 mM). Erythrocyte encapsulated
lactate oxidase however was able to provide a constant catabolic rate under the same range of blood
lactate concentrations, but was limited by the generation of hydrogen peroxide which is toxic to the
erythrocytes. The co-encapsulation of both enzymes provided a significant rate of lactate metabolism
in vitro, over a range of 1–30 mM lactate and counteracted the production of hydrogen peroxide by
increasing the amount of glucose metabolized in the pentose phosphate pathway. The in vivo efficacy
of the loaded cells in removing blood lactate in the mouse, however, could not be demonstrated due to
the high aerobic capacity and high lactate metabolism of this species [61].
3.3.5. Glucose-6-Phosphate Dehydrogenase Deficiency
Glucose-6-phosphate dehydrogenase (EC 1.1.1.49) deficiency (OMIM # 300908) is caused by
mutations in the G6PD gene. The enzyme catalyzes nicotinamide adenine dinucleotide phosphate
(NADP) to its reduced form, NADPH, in the pentose phosphate pathway. NADPH protects cells from
oxidative damage and because mature erythrocytes cannot generate NADPH by any other pathway,
a deficiency in glucose-6-phosphate dehydrogenase increases the vulnerability of erythrocytes to
oxidative stress. The common clinical manifestations of the disease are neonatal jaundice and acute or
chronic hemolytic anemia triggered by exogenous agents [62]. Gerli and co-workers demonstrated
that human glucose-6-phosphate dehydrogenase deficient erythrocytes loaded with enzyme extracted
from yeast were able to acquire some capacity to reduce glutathione [63]. In the study of Morelli et al.,
homogeneous human glucose 6-phosphate dehydrogenase was successfully encapsulated into the
erythrocytes of individuals affected by glucose 6-phosphate dehydrogenase deficiency, to levels
observed in unaffected erythrocytes, with a consequent normalization of the pentose phosphate
pathway [64].
3.3.6. Adenosine Deaminase Deficiency
The application of the erythrocyte carrier as an enzyme replacement for adenosine deaminase
deficiency (OMIM # 608958) due to severe combined immunodeficiency was explored by
Bax et al., [65–69]. The disorder is caused by mutations in the ADA gene which encodes for
adenosine deaminase (EC 3.5.4.4), the enzyme responsible for catalyzing the irreversible deamination
of adenosine and 2’-deoxyadenosine in the purine catabolic pathway. The subsequent accumulation
of 2’-deoxyadenosine results in its preferential phosphorylation to deoxyadenosine triphosphate
(dATP) which accumulates intracellularly to high levels, resulting in an impairment of lymphocyte
differentiation and proliferation through the inhibition of ribonucleotide reductase. The disease is
characterized by low levels of immunoglobulins, a virtual absence of T-lymphocytes and markedly
reduced levels of B-lymphocytes and natural killer cells [70]. The encapsulation of native adenosine
deaminase and the licensed pharmaceutical preparation, polyethylene glycol-conjugated adenosine
deaminase (pegademase), within human erythrocyte carriers was investigated. The rationale was to
prolong the in vivo circulatory half-life of these enzyme preparations and maintain therapeutic blood
levels. The efficiencies of native enzyme and pegylated enzyme encapsulation were 50% and 9%,
respectively, thus indicating that the polyethylene glycol side-chains were impeding the encapsulation
of the pegylated preparation. The biochemical characteristics and the osmotic fragility of loaded
cells were not adversely affected by the encapsulation of either enzyme preparation [65,66,68]. In vivo
survival studies of pegademase-loaded erythrocytes were conducted by labeling with Chromium [51Cr]
and infusing into an ADA-deficient adult patient and demonstrated a mean cell half-life of 16 days.
Erythrocyte encapsulated pegademase and native ADA had in vivo circulatory half-lives of 20 and
12.5 days, respectively; these are substantially greater than the plasma half-lives of the unencapsulated
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preparations, which are less than six days [68]. A clinical evaluation of erythrocyte-encapsulated
native adenosine deaminase therapy was conducted over a period of nine years in a single patient
who received a total of 225 infusions every 2–3 weeks. Observations included a reduction in the
erythrocyte dATP concentration to between 24 and 44 µmol/L, compared to 234 µmol/L on diagnosis
and a normalization of serum immunoglobulin levels. Also reported were a reduction in the frequency
of respiratory problems and a decline in the forced expiratory volume in one second and vital capacity
reduced compared with the four years preceding erythrocyte therapy [69].
3.3.7. Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
MNGIE (OMIM # 603041) is an ultra-rare, fatal disorder caused by mutations in the
nuclear TYMP gene which leads to a deficiency in thymidine phosphorylase activity (EC 2.4.2.4).
Thymidine phosphorylase plays a pivotal role in the deoxyribonucleoside salvage metabolic pathway
through catalyzing the reversible phosphorylation of thymidine and 2’-deoxyuridine to 2-deoxyribose
1-phosphate and their respective bases, thymine and uracil. In the absence of thymidine phosphorylase
activity there is a systemic accumulation of thymidine and 2’-deoxyuridine which generate
imbalances within the mitochondrial deoxyribonucleotide pools, causing mitochondrial DNA (mtDNA)
point mutations, depletion and deletion abnormalities—and ultimately mitochondrial dysfunction.
The disorder is characterized by gastrointestinal dysmotility, cachexia, peripheral neuropathy,
ophthalmoplegia, ptosis and leukoencephalopathy [71]. Although there are no licensed therapies for
patients with MNGIE, there are a number of experiment treatment approaches under investigation
and this is attributed to MNGIE being one of the few mitochondrial disorders where the molecular
abnormality is metabolically and physically accessible to manipulation. Erythrocyte encapsulated
thymidine phosphorylase (EE-TP) is one of these experimental approaches, where recombinant E. coli
enzyme was employed as the source of enzyme [71–74]. In the first proof of concept study, one dose
of EE-TP (1020 units encapsulated within 20.25 × 1010 erythrocytes) was administered to a patient
with MNGI.E. Three days post infusion, there was a reported decrease in the urinary excretion of
thymidine and 2’-deoxyuridine, to 6% and 13%, respectively of the amounts excreted pre-therapy.
Plasma metabolites concentrations were also shown to decrease in parallel [75]. Pre-clinical studies
conducted in the mouse and dog revealed no safety issues that would preclude a clinical study of
EE-TP, other than the production of anti-thymidine phosphorylase antibodies in a small proportion of
animals [76,77]. Based on these encouraging results, a compassionate use program was conducted
in four further patients, with participants receiving treatment in accordance with the provisions
of Schedule 1 of the Medicines for Human Use (marketing authorizations, etc.) Regulations SI
1994/3144, where schedule 1 provides an exemption from the need for a marketing authorization for a
relevant medicinal product, which is supplied on an individual patient basis to fulfil a “special need”.
A chromium [51Cr]–labeling study of EE-TP was conducted in one patient to evaluate the in vivo survival
characteristics of the patient’s enzyme-loaded erythrocytes and this revealed a normal circulating mean
cell life and half-life of 108 and 32 days, respectively [78]. The administration of doses ranging between
3.7 to 108 U/kg body weight/4 weeks indicated that doses greater than 47 U/kg/4 weeks resulted
a greater reduction or an elimination of plasma and urine metabolites. One patient was reported to gain
four kg in weight, three months after initiating therapy and this coincided with a decrease in nausea
and vomiting, increased ability to walk longer distances and an increase in the physical and mental
components of the SF36 health and well-being survey. A second patient showed significant clinical
improvements in bilateral muscle power, gait and balance, sensory ataxia and fine finger function, after
23 months of EE-TP therapy. In addition, a weight gain of 5.8 kg was reported and a fall in plasma
creatine kinase activity from 1200 U/L pre-therapy to levels within the normal reference range. Patient
reported outcomes included an ability to walk longer distances, climb stairs without assistance, tie shoe
laces, feel the sensation of sand, and a return to weight training and guitar playing [78–80]. Adverse
events for EE-TP that were recorded in this compassionate study included nausea, coughing spasms
and erythema of the face and neck in two of the four patients. These were transient in nature, occurring
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within the first five minutes of EE-TP infusion and did not lead to patient discontinuation of EE-TP
therapy. Pre-medication with antihistamine, corticosteroid anti-inflammatory and anti-emetic drugs
provided a strategy for successfully managing these reactions [78,79]. Specific antibodies to thymidine
phosphorylase were detected in one patient, after the tenth treatment cycle. However, this did
not raise any concerns with regard to neutralizing antibodies as the efficacy of encapsulated
thymidine phosphorylase in metabolizing the plasma metabolites improved over the 5.5 years of EE-TP
administration to this patient, and positive clinical responses to treatment continued to be recorded [81].
The development of specific antibodies is not surprising considering that senescent erythrocytes are
naturally sequestered from the vascular compartment by macrophages of the monocyte–macrophage
system, where macrophages are able to present peptides to T-lymphocytes [82]. EE-TP has received
MHRA clearance for a Phase II, multi-center, multiple-dose, open-label trial without a control to
determine the safety, tolerability, pharmacodynamics and efficacy this treatment approach in patients
with MNGIE (https://clinicaltrials.gov/ct2/show/NCT03866954) [83]. EE-TP has Orphan designation by
the EMA and FDA.
3.3.8. Hyperuricemia
Due to the loss of uricase (EC 1.7.3.3) activity during the evolution of hominids, uric acid is
the end product of purine metabolism in humans and other higher primates and is excreted in the
urine. Hyperuricemia is caused by abnormally elevated concentrations of blood uric acid and arises
through several mechanisms, including reduced renal excretion or increased uric acid production.
The concept of utilizing the erythrocyte as a mechanism for degrading extracellular molecules was
investigated by Ihler et al. through examining the in vitro metabolism of extracellular uric acid by
human erythrocytes-loaded with uricase. Uric acid was shown to be transported into enzyme-loaded
cells at the same rate as in native erythrocytes, however, the generation of hydrogen peroxide through
the metabolism of uric acid to allantoin raised the concern of inducing oxidative stress damage [84].
To address this, Magnani et al. coupled uricase to the extracellular human erythrocyte membrane
by a biotin–avidin–biotin–enzyme bridge, and in doing so, demonstrated a more efficient in vitro
metabolism of uric acid, compared to that by encapsulated enzyme [85].
3.3.9. Phenylketonuria
Phenylketonuria (OMIM # 261600) is an autosomal recessive disorder caused by mutations in the
PAH gene, leading to a deficiency in the enzyme responsible for the hydroxylation of phenylalanine to
tyrosine, phenylalanine hydroxylase (EC 1.14.16.1). If untreated, phenylketonuria can result in impaired
postnatal cognitive development resulting from a neurotoxic effect of hyperphenylalaninemia [86].
Another enzyme capable of metabolizing phenylalanine is phenylalanine ammonia lyase (EC 4.3.1.24).
This enzyme is not expressed in mammals, but is expressed in plants, some bacteria, yeast and fungi and
catalyzes the conversion of phenylalanine to ammonia and trans-cinnamic acid. Its potential application
via erythrocyte encapsulation as a therapy for phenylketonuria was first proposed by Sprandel and
Zoller, with a short-term in vivo study in mice demonstrating the effectiveness of this strategy [87].
Erythrocytes loaded with recombinant Chromobacterium violaceum phenylalanine hydroxylase, together
with the cofactor tetrahydrobiopterin, were shown to reduced blood phenylalanine levels when
administered to wild-type mice, but not when administered to the BTBR Pahenu2 phenylketonuria mouse
model [88]. In contrast, the repeated administration of erythrocytes loaded with recombinant Anabaena
variabilis phenylalanine ammonia lyase (rAvPAL) at 9–10-day intervals for 10 weeks, was able to provide
a sustained reduction in blood phenylalanine levels in the BTBR Pahenu2 mouse model and also reverse
fur pigmentation. Although, anti-enzyme antibodies were generated, these did not affect the efficacy of
the encapsulated enzyme [89]. More recent studies examining the clinical efficacy of erythrocyte-loaded
rAvPAL in the early treatment of the BTBR Pahenu2 mouse demonstrated a normalized of blood and
brain phenylalanine concentrations and prevented cognitive developmental failure, depletion of brain
serotonin, dendritic spine abnormalities and myelin basic protein reduction [90]. Rubius Therapeutics,
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Inc received FDA approval for a Phase Ib clinical trial of genetically engineered erythrocytes expressing
phenylalanine ammonia lyase (RTX-134). This approach involves the genetic engineering of CD34+ cells,
collected from a healthy O negative donor, with a lentiviral vector to express enzyme phenylalanine
ammonia lyase within the cells. The cells are expanded and differentiated until the nucleus is ejected,
resulting in the mature reticulocyte. The trial is reported to be active, but no longer recruiting, and is
designed to determine a preliminary dose and to inform on a dosing schedule that is deemed safe,
tolerable and potentially effective (https://clinicaltrials.gov/ct2/show/NCT04110496). Recent media
coverage has, however reported that the trial will be discontinued due to results from the first patient
being uninterpretable. This is thought to be due to the low dose of cells administered and the lack of
sensitivity of the flow cytometry assay used to detect circulating cells.
3.4. Antitumor Therapy
The implementation of the erythrocyte carrier in antitumor therapy has focused on the use of
encapsulated enzymes and represents one of the most clinically advanced applications is for the
treatment of acute lymphoblastic leukemia (ALL). This strategy is based on tumor cells not being
able to synthesize adequate amounts of amino acids and therefore depend on extracellular sources.
The administration of specific enzymes enables the depletion of plasma amino acids, thus starving the
tumor cells of amino acids necessary for DNA, RNA and protein synthesis and leading ultimately to
cell death. The antitumor characteristics of L-asparaginase (EC 3.5.1.1) was first investigated by Kidd,
who reported lymphoma regression in mice and rats in response to guinea pig plasma [91]. In the early
1970s, native Erwinia chrysanthemi and E. coli-derived l-asparaginase were introduced into chemotherapy
protocols for the treatment of ALL. However, its use was associated with toxicity against the liver and
pancreas. High immunogenicity, manifesting as hypersensitivity reactions and/or the neutralization of
asparaginase activity without any signs of hypersensitivity were also observed. The enzymes had
a short circulatory half-life, ranging between 8 and 30 h thus necessitating frequent infusions [92].
Pegylated formulations of E. coli l-asparaginase were developed to overcome these limitations,
however these preparations are associated with hepatotoxicity, pancreatitis and thrombosis [93].
Updike et al. were the first to employ the erythrocyte carrier as a strategy to counteract the problems
of antigenicity and host proteolytic degradation of asparaginase. In vivo studies demonstrated
that circulating asparaginase activity in monkeys injected with enzyme-loaded erythrocytes was
two orders of magnitude higher than that in animals injected with native asparaginase [94,95].
In addition, monkeys that received a single injection of erythrocyte-loaded enzyme were able to
suppress plasma asparagine concentrations for 20 days compared to 10 days for animals that received
the native enzyme [96]. Further preliminary in vivo studies in the mouse and human demonstrated
the safety of asparaginase-loaded erythrocytes and their efficacy in reducing plasma asparagine
concentrations [96–100].
Erytech Pharma have developed a number of programs to further investigate the safety and
efficacy of erythrocyte encapsulated asparaginase for the treatment of several types of cancers. In their
Phase I/II study of E. coli erythrocyte-encapsulated l-asparaginase (GRASPA) conducted in adults and
children with ALL, they were able to demonstrate an effective depletion of L-asparagine. A single
injection of the highest dose (150 IU/kg) was shown to provide similar results to eight intravenous
injections of 10,000 IU/m2 of the native enzyme. In addition, compared to the native enzyme,
GRASPA exhibited a reduction in the number and severity of allergic reactions and a trend towards
less coagulation disorders [101]. A subsequent Phase II trial evaluating the safety and efficacy of
GRASPA was conducted in patients 55 years of age and older with Philadelphia chromosome-negative
ALL. The primary efficacy endpoint of asparagine depletion <2 µmol/L for at least seven days was
achieved in 85% and 71% of patients who received 100 and 150 IU/kg, respectively, but not with
those patients who received 50 IU/kg. Although no dose limiting toxicity was observed at the lowest
dosage, in the 100 IU/kg and 150 IU/kg cohorts, toxicities were 15% and 36%, respectively. This
suggested that the 100 IU/kg dose had the best safety/efficacy profile for these elderly patients [102].
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Erythrocyte encapsulated asparaginase was subsequently extended to a Phase I clinical trial for
the treatment of patients with pancreatic adenocarcinoma with null/low asparagine synthetase
expression. The intervention (ERY–ASP) was well tolerated by patients, and demonstrated no dose
limiting toxicities reported [103]. A follow-on Phase IIb study evaluating erythrocyte-encapsulated
asparaginase (relabeled as eryaspase) in combination with chemotherapy in second-line advanced
pancreatic adenocarcinoma was conducted. This demonstrated significantly prolonged overall survival
and progression free survival compared with chemotherapy alone, with a 40% reduction in the risk of
death on average over time. The therapy combination was shown to be generally well tolerated and
revealed no unexpected safety findings [104]. A Phase III study in patients with ductal adenocarcinoma
of the pancreas who have failed one prior line of systemic anticancer therapy for advanced pancreatic
cancer and have measurable disease is currently active and recruiting. The primary outcome measure
is whether the addition of eryaspase to chemotherapy improves overall survival when compared to
chemotherapy alone (https://clinicaltrials.gov/ct2/show/NCT03665441). Following the positive clinical
data obtained from the pancreatic cancer studies, Erytech are now expanding their solid tumor studies
to include selected metastatic triple-negative breast cancer. The ongoing Phase II/III trial is evaluating
eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy
alone as a first-line treatment (https://clinicaltrials.gov/ct2/show/NCT03674242).
Other enzymes, with relevance to tumor starvation which have been encapsulated include
methionine-γ-lyase (EC 4.4.1.11) and arginine deiminase (EC 3.5.3.6). The administration of
erythrocyte encapsulated Pseudomonas putida methionine-γ-lyase to mice grafted with human gastric
adenocarcinoma and glioblastoma was effective in providing a sustained and significant plasma
methionine depletion in vivo and a reduction in tumor growth [105]. A significant inhibition of tumor
growth was observed in mice bearing orthotopic EMT-6 syngeneic breast carcinoma when infused with
erythrocyte-encapsulated methionine-γ-lyase at a dose of 60 U/kg and in combination with anti-mouse
PD-1 antibody, compared to the separate entities. Survival time was 35 days for the combined therapy,
compared to 23 days for the separate therapies [106]. With regard to erythrocyte encapsulated arginine
deiminase, a dose of 10.4 IU/mL administered to CD1 mice was shown to completely deplete plasma
arginine over a period of five days compared to the same dose of free enzyme. The depletion was
sustained for 24 h, with the plasma levels returning to baseline by 2.5 days [107].
4. Challenges and Limitations of Erythrocyte-Based Enzyme Therapy
The limitation of the erythrocyte enzyme carrier is that its metabolic capacity is restricted to the
vascular compartment and monocyte–macrophage system. For the former, a further restriction for the
encapsulated enzyme, would be the inability of the enzyme’s substrate to permeate the erythrocyte
membrane. Thus, the spectrum of clinical applications to which the erythrocyte enzyme carrier can be
applied to is fairly narrow. As with most cell-based therapies, the translation of the erythrocyte carrier
into the clinical setting faces many complex process-related and regulatory challenges. The enzyme to be
encapsulated or conjugated to the erythrocyte membrane will require manufacture in compliance with
current good manufacturing practice (cGMP). Although advancements in the field of recombinant DNA
biotechnologies have facilitated the manufacture of therapeutic enzymes, many challenging activities
exist, including full characterization of cell banks, process- and product-related impurities and enzyme;
validation of analytical procedures; formulation design; and stability studies. The transition of the
manufacture of the erythrocyte carrier from a laboratory-based scale, to a scale that is clinically relevant
is a critical step in the development pathway. Manufacture can be via a decentralized automated
process, such as the Red Cell Loader as employed by Erydel or via a centralized process as used by
Erytech Pharma [108,109]. Either way, the process will need to be performed in a closed-circuit system,
using single use, sterile disposables. A key regulatory requirement is the manufacture of a reproducible
product. Standardizing the loading procedure (and thus dose) when autologous erythrocytes are
employed can be difficult to achieve, and may necessitate the consideration of individualized metrics
such as patient hematocrit or red blood cell count in the manufacturing process. To minimize
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substantial differences in the quality of the end product and to produce a consistent encapsulation
rate, Erytech Pharma who employ homologous donated erythrocytes, adjust the process operating
conditions such as erythrocyte flow rate and osmolality of buffers according to the osmotic fragility of
the initial donor erythrocyte pellet [109]. Prior to clinical batch release by a pharmacist, the product will
need to conform to product specifications. For erythrocyte carriers manufactured from homologous
blood, the 72-h shelf-life specified by Erytech provides sufficient time to conduct the necessary
tests [109]. However, erythrocyte carriers manufactured from blood collected from autologous blood
require a much shorter shelf-life (30 min) thus providing a major hurdle to testing. The MHRA
approved Phase II trial of EE-TP was able to navigate this issue by proposing a retrospective testing of
two of the release parameters. The impact of manufacturing process and chemical modification (where
enzymes are conjugated to the erythrocyte membrane) on the function, viability and biocompatibility
of the erythrocyte will also need to be established to ensure safety of the medicinal product.
5. Conclusions
The erythrocyte carrier has the advantage of counteracting some of the key issues associated with
the administration of free enzymes by virtual of shielding the enzyme from the immune system and
plasma proteases, and thereby enhance the circulatory half-life and minimize immunogenic reactions.
The feasibility of erythrocyte-mediated enzyme therapy to deplete pathological molecules in the
circulation has been investigated by many workers using animal models and humans. This paper
provides an overview of the immense range of applications that have been investigated, covering the
early studies of the 1970s up to the more recent biomedical applications that have overcome the process
and regulatory challenges that face cell therapy development and have reached the clinic; these are
summarized in Table 1. Although there are currently no licensed erythrocyte-mediated enzyme
therapeutics, this is very likely to change over the next few years, with several products undergoing
advanced clinical development for conditions where there are unmet needs.
Table 1. Summary of in vitro, in vivo and clinical applications of erythrocyte-mediated enzyme therapy.
Therapeutic
Application
Therapeutic
Target/Disorder Encapsulated/Conjugated Enzyme Investigations
Detoxification
of exogenous
chemicals
Cyanide [8–13] Rhodanase Mouse in vivo
Paraoxon [14,15] Phosphotriesterase Mouse in vivo
Paraoxonase Mouse in vivo
Ethanol [16–20] Acetaldehyde dehydrogenase Mouse in vivo
Alcohol dehydrogenase/aldehyde
dehydrogenase
Mouse in vitro/in vivo
Human in silico/in vitro
Methanol [21,22] Alcohol oxidase Mouse in vivo
Mouse in vivoFormate dehydrogenase
Lead [23–25] δ-aminolevulinic acid dehydratase Mouse in vitro/in vivoHuman clinical
Hydrogen gas [26] Hydrogenase Human in vitro
Thrombolytic
therapy
Plasminogen [27–31]
Urokinase Human in vitroMouse in vivo
Streptokinase Human in vitroMouse in vivo
tPA Human in vitroMouse/rat in vivo
Brinase Rabbit in vitro
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Table 1. Cont.
Therapeutic
Application
Therapeutic
Target/Disorder Encapsulated/Conjugated Enzyme Investigations
Treatment of
metabolic
disease
Sphingolipids
(Lysosomal storage
disorders) [32–37]
β-glucosidase Human in vitro
β-galactosidase Human in vitro
β-glucuronidase Mouse in vivo
β-glucocerebrosidase Human in vitro/clinical
Alglucerase Human in vitro
Ammonia
(hyperammonemia)
[38–42]
l-glutamate dehydrogenase Human in vitroMouse in vivo
Glutamine synthetase Mouse in vivo
Glutamate dehydrogenase/alanine
aminotransferase
In silico
Human in vitro
Mouse in vivo
Arginine and
ammonia (arginase-1
deficiency) [43]
Arginase Human in vitro
Urea and ammonia
(chronic renal failure)
[44–47]
Urease/alanine dehydrogenase Human in vitroSheep in vivo
Glucose
(hyperglycemia)
[48–51]
Hexokinase Human in vitro
Glucose oxidase Human in vitroMouse in vitro/in vivo
Hexokinase/glucose oxidase Human in vitroMouse in vitro/in vivo
Lactate
(hyperlactatemia)
[52]
Lactate 2-mono-oxygenase Mouse/human in vitro
Lactate oxidase Mouse/human in vitro
Lactate 2-mono-oxygenase/ lactate
oxidase
Mouse in vitro/in vivo
Human in vitro
NADP
(Glucose-6-phosphate
dehydrogenase
deficiency) [3,54]
Glucose-6-phosphate
dehydrogenase Human in vitro
Adenosine and
2‘-deoxyadenosine
(Adenosine
deaminase
deficiency) [55–59]
Adenosine deaminase
Pegademase
Human in vitro/in vivo
Human in vitro/clinical
Thymidine and
2’-deoxyuridine
(MNGIE) [60–72]
Thymidine phosphorylase Mouse/dog in vivoHuman Phase II
Uric acid
(hyperuricemia)
[73,74]
Uricase Human in vitroMouse in vivo
Phenylalanine
(phenylketonuria)
[75–78]
Phenylalanine ammonia lyase Mouse in vitro/in vivo
Phenylalanine hydroxylase Mouse in vivo
RTX-134 Human Phase Ib
Antitumor
therapy
Asparagine
(acute lymphoblastic
leukemia) [79–90]
Asparaginase
GRASPA
Monkey in vivo
Human Phase I/II
Asparagine
(pancreatic
adenocarcinoma)
[91,92]
ERY-ASP
Eryaspase
Human Phase I
Human Phase IIb/
Phase III
(triple negative
breast cancer) Eryaspase Human Phase II/III
Methionine (gastric
adenocarcinoma,
glioblastoma, breast
carcinoma) [93,94]
Methionine-γ-lyase Mouse in vivo
Arginine [95] Arginine deiminase Mouse in vivo
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